References
- Kudoh S, Uetake T, Hagiwara K et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse pan-bronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25: 632–42 (in Japanese).
- Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002; 360: 978–84.
- Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin sup-presses interleukin 6 expression by human bronchial epitherial cells; a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun. 1995; 210: 781–6.
- Iino Y, Toriyama M, Kudo K, Natori Y, You A. Erythro-mycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol Suppl. 1992; 157: 16–20.
- Oishi K, Sonoda F, Kobayashi S et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145–52.
- Kadota J, Sakito O, Kohno S et al. A mechanism of eryth-romycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147: 153–9.
- Keicho N, Kudoh S, Yotsumoto H et al. Erythromycin pro-motes monocyte to macrophage differentiation. J Antibiot (Tokyo) 1994; 47: 80–9.
- Keicho N, Kudoh S, Yotsumoto H et al. Anti-lymphocytic activity of erythromycin distinct from that of FK506 or cy-closporin A. J Antibiot (Tokyo) 1993; 46: 1406–13.
- Forsgren A, Banck G, Beckman H, Bellahsene A. Antibi-otic-host defence interactions in vitro and in vivo. Scand J Infect Dis 1980; Suppl 24: 195-203.
- Konno S, Adachi M, Asano K et al. Inhibition of human T-lymphocyte activation by macrolide antibiotic, roxithromycin. Life Sci 1992; 51: 231–6.
- Reinherz EL, Kung PC, Goldstein G, Schlossman SF. Sep-aration of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci USA 76: 4061–5, 1979.
- Silva JR, Jones JA, Cole PJ, Poulter LW. The immuno-logical compotent of the cellular inflammatory infiltrate in bronchiectasis. Thorax 1989; 44: 668–73.
- Mukae H, Kadota J, Kohno S et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152: 613–8.
- Kawakami K, Kadota J, Lida K et al. Phenotypic charac-terization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the im-portance of cytotoxic T cells. Clin Exp Immunol 1997; 107: 410–6.
- Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology, 2006; 11: 249–61.
- Haring JS, Badovinac VP, Harty JT. Inflaming the CD8+ T cell response. Immunity, 2006; 25: 19–29.
- Tetley TD. Inflammatory cells and chronic obstructive pul-monary disease. Curr Drug Targets-Inflamm Allergy, 2005; 4: 607–18.
- Hodge S, Hodge G, Nairn J, Holmes M, Reynolds PN. In-creased airway granzyme b and perforin in current and ex-smok-ing COPD subjects. COPD, 2006; 3: 179–87.